Polar Capital LLP lessened its stake in Sientra Inc (NASDAQ:SIEN) by 9.6% in the 4th quarter, HoldingsChannel reports. The fund owned 903,900 shares of the medical instruments supplier’s stock after selling 96,100 shares during the period. Polar Capital LLP’s holdings in Sientra were worth $11,489,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Sientra in the fourth quarter valued at $29,000. Great West Life Assurance Co. Can acquired a new position in Sientra in the fourth quarter valued at $64,000. Dimensional Fund Advisors LP acquired a new position in Sientra in the fourth quarter valued at $135,000. Citigroup Inc. boosted its stake in Sientra by 101.7% in the fourth quarter. Citigroup Inc. now owns 19,000 shares of the medical instruments supplier’s stock valued at $241,000 after acquiring an additional 9,579 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in Sientra by 50.6% in the fourth quarter. Rhumbline Advisers now owns 30,301 shares of the medical instruments supplier’s stock valued at $385,000 after acquiring an additional 10,180 shares in the last quarter. Institutional investors own 92.79% of the company’s stock.
Shares of SIEN opened at $8.34 on Friday. Sientra Inc has a fifty-two week low of $7.74 and a fifty-two week high of $26.79. The stock has a market cap of $325.46 million, a PE ratio of -2.57 and a beta of -0.04. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.77 and a quick ratio of 2.34.
Several equities analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Sientra from a “sell” rating to a “hold” rating in a research note on Friday, November 16th. BidaskClub upgraded shares of Sientra from a “strong sell” rating to a “sell” rating in a research note on Monday, January 7th. Maxim Group upgraded shares of Sientra from a “hold” rating to a “buy” rating in a research note on Wednesday, December 19th. ValuEngine downgraded shares of Sientra from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 24th. Finally, William Blair downgraded shares of Sientra from an “outperform” rating to a “market perform” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $19.50.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Want to see what other hedge funds are holding SIEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sientra Inc (NASDAQ:SIEN).
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.